May 26, 2021
Company recognized for its innovative contributions to the life sciences industry in North Carolina DURHAM, N.C., May 26, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today...
May 21, 2021
Laboratory and pre-clinical models of whole-lung engineering inform roadmap for building a functional lung alveolus, which is the key building block for making a functional lung Data presented at 38th Annual Meeting of the Japanese Association for Chest Surgery DURHAM, N.C., May 21, 2021 (GLOBE...
May 19, 2021
Proven CFO with extensive financial leadership and commercialization experience, including multiple publicly listed life sciences companies DURHAM, N.C., May 19, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered...
Apr 14, 2021
DURHAM, N.C., April 14, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the closing of a secured debt financing facility with Silicon Valley Bank for up to $50...
Feb 17, 2021
Humacyte aims to transform medicine with off-the-shelf, universally implantable, bioengineered human tissue available at commercial scale. Transaction values Humacyte at a pre-money valuation of $800 million with existing Humacyte shareholders rolling over 100% of their equity into equity of the...
Displaying 51 - 60 of 68